Press Releases Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:27:33 13/03/2026 GMT			5-day change	1st Jan Change
96.24 ^USD	+1.23%		-2.37%	+20.62%

03-04	Revolution Medicines Insider Sold Shares Worth $3,644,354, According to a Recent SEC Filing	MT
03-03	Revolution Medicines, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 09:50 AM

Press Releases

02-25	Revolution Medicines : Corporate Presentation (b5f2fd)	PU
02-25	Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress	AQ
02-24	Revolution Medicines : to Participate in TD Cowen 46th Annual Health Care Conference	PU
02-24	Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference	AQ
02-18	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026	AQ
02-04	Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026	AQ
01-29	Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor	AQ
01-23	To Monetize Or Not To Monetize? The Question Late-Stage Life Sciences Companies Should Be Asking	AQ
01-12	Revolution Medicines : Corporate Presentation (e71a1a)	PU
01-08	Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib	AQ
01-05	Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference	AQ
12-18	Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy	AQ
11-05	Revolution Medicines : Corporate Presentation (5ec420)	PU
11-05	Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress	AQ
11-04	Revolution Medicines to Participate in November 2025 Investor Conferences	AQ
29/10/25	Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025	AQ
27/10/25	Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer	AQ
22/10/25	Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor	AQ
17/10/25	Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program	AQ
29/09/25	Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer	AQ
10/09/25	Revolution Medicines : Metastatic Pancreatic Cancer Update (694310)	PU
10/09/25	Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma	AQ
07/08/25	Revolution Medicines : Corporate Presentation (87230b)	PU
06/08/25	Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress	AQ
30/07/25	Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025	AQ